[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wet-age-related-macular-degeneration-wamd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wet-age-related-macular-degeneration-wamd":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,69,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100602878","phase-3-high-dose-hd-aflibercept-switch-in-neovascular-age-related-macular-degeneration-namd-to-load-or-maintain-heirloom-100602878",false,"NCT07129239","High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)","HEIRLOOM","Inclusion Criteria:\n\n* Patients over the age of 18\n* Patients with neovascular AMD\n* Patients who have received aflibercept 2mg for a minimum of 3 loading injections plus 2 maintenance injections.\n* Can include 1 or 2 eyes per patient if one or both meet study criteria.\n\nExclusion Criteria:\n\n* Patients with other maculopathy, including but not limited to:\n* Polypoidal choroidal vasculopathy\n* Macular dystrophies (ie. Pattern dystrophy, central areolar etc.)\n* Toxic\u002Fdrug induced maculopathies\n* Disciform scar\n* Subfoveal atrophy\n* Previous Photodynamic Therapy (PDT) or focal laser\n* Is currently enrolled in another clinical study or observational study\n* Active use of a different agent in the fellow eye, to avoid cross-over effects of anti Vascular Endothelial Growth Factor (VEGF) administration to the fellow eye\n* If the patient is pregnant","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg).\n\nEYLEA® HD is approved by Health Canada has been tested in large clinical trials involving thousands of patients around the world and has been shown effective in the treatment of wAMD. The treatment regimen used in these trials involved 3 initial monthly injections of EYLEA® HD followed by an extension of the treatment interval on the 4th visit. This was necessary since all patients in this study did not previously have treatment injections for wAMD.\n\nCurrently there is not enough information on the best treatment regimen to use for patients that are switched to EYLEA® HD from EYLEA®.\n\nHealth Canada currently recommends that EYLEA® HD is administered every month for the first 3 doses, followed by a treatment every 8 to 16 weeks.\n\nA total of 180 patients \\>18 years of age will participate in this study, which will be conducted at the Clinique de Retine de l'Est in Montreal, Quebec, Canada.",[26],"Wet Age-related Macular Degeneration (wAMD)","NOT_YET_RECRUITING","2025-08-11",{"date":30,"type":31},"2025-08-19","ACTUAL",{"date":33,"type":20},"2025-08-20",{"date":35,"type":20},"2027-02",{"name":37,"class":38},"Clinique de Retine de l'est","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100584373","early-phase-1-to-evaluate-the-safety-and-preliminary-efficacy-of-intravitreal-exg202-injection-in-patients-with-wet-neovascular-age-related-macular-degeneration-wamd-100584373","NCT06888492","To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)","An Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)","Inclusion Criteria:\n\n1. Male or female, aged ≥50 years old;\n2. The study eye must meet the following criteria:\n\n   A. Diagnosed of wAMD and current active lesions; active, defined as the presence of any of the following lesions in the macular area upon OCT examination: a) intraretinal hemorrhage or fluid; b) subretinal fluid; c) subretinal hemorrhage; B. The BCVA score tested during screening using the ETDRS eye chart (see Appendix 3 for details) must be between 73-19 letters (including boundary values), (equivalent to Snellen visual acuity of 20\u002F40 to 20\u002F400);\n3. Clinically meaningful response to standard anti-VEGF therapy within 6 months before screening or during the lead-in period of screening.\n4. The subject has clear refractive media and sufficient pupil dilation at the time of screening to obtain high-quality retinal images for confirmation of diagnosis;\n5. Subjects (including male subjects) have no pregnancy plans during the screening period and the entire trial period and voluntarily take effective contraceptive measures and have no sperm or egg donation plans;\n6. Voluntarily participate in this clinical trial, understand the research procedures and sign the informed consent form before screening; have good compliance and are willing to abide by the research procedures.\n\nExclusion Criteria:\n\n1. The study eye has any eye disease other than wAMD that may affect central vision and\u002For macular detection (such as macular hole, macular epiretinal membrane, etc.);\n2. The study eye has a history of retinal detachment or retinal detachment during the screening period (such as rhegmatogenous retinal detachment, tractional retinal detachment, etc.);\n3. The study eye has MNV caused by reasons other than wAMD (such as diabetic retinopathy, pathological myopia, retinal vein occlusion, angioid streak disease, ocular histoplasmosis, trauma, etc.), and a history of macular pathology unrelated to wAMD;\n4. The study eye plans to undergo any intraocular surgery during the study period;","50 Years",{"count":49,"type":20},8,[51],"EARLY_PHASE1","The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of intravitreal injection of EXG202 in subjects with neovascular age-related Macular Degeneration (nAMD).",[26,54],"Wet Age-related Macular Degeneration",[56,57],"wAMD","AAV","2025-03-20",{"date":60,"type":31},"2025-03-21",{"date":62,"type":20},"2025-03-28",{"date":64,"type":20},"2026-04-30",{"name":66,"class":67},"Guangzhou Jiayin Biotech Ltd","INDUSTRY",2,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":39},"100580595","phase-2-efficacy-and-safety-of-al-001-ophthalmic-injection-in-subjects-with-wamd-100580595","NCT06839339","Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD","A Phase II, Randomized, Positive-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Single Suprachoroidal Space Injection of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Macular Degeneration (wAMD)","Inclusion Criteria:\n\n1. Age≥ 50 and ≤ 85.\n2. The study eye was diagnosed with subfoveal active choroidal neovascularization (CNV) lesions secondary to wAMD.\n3. The study eye has response to anti-VEGF injections.\n4. The subject or their legal representative agrees to participate in this study and signs a written ICF.\n\nExclusion Criteria:\n\n1. Non-wAMD induced CNV or macular edema in the study eye.\n2. Non-wAMD induced eye conditions that may affect central vision or medical history that may seriously affect central vision in the study eye.\n3. Uncontrolled glaucoma in the study eye.\n4. History of vitreoretinal surgery, antiglaucoma trabeculectomy, or other anti-glaucoma filtering surgery in the study eye.\n5. Refractive interstitial opacity that significantly affects visual function assessment or fundus examination in the study eye.\n6. Ametropia (high myopia or high hyperopia) \\> 8.0D in the study eye, or significant posterior scleral staphyloma in the study eye.\n7. Malignant tumor in any eye, including but not limited to eye lymphoma or choroidal melanoma.\n8. None of intraocular inflammation in the study eye.\n9. Other conditions that may affect compliance or may not be suitable to participate in this trial in the opinion of investigator.","85 Years",{"count":78,"type":20},40,[80],"PHASE2","This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion\u002Fexclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will be randomized in Cohorts 1 and 2 to receive AL-001 administered via suprachoroidal space injection, Cohort 3 to receive Aflibercept.",[26],"2025-02-17",{"date":85,"type":31},"2025-02-21",{"date":87,"type":20},"2025-02-18",{"date":89,"type":20},"2027-01-30",{"name":91,"class":67},"Beijing Anlong Biopharmaceutical Co., Ltd.",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":39},"100571327","long-term-follow-up-study-of-al-001-ophthalmic-injection-in-subjects-with-wamd-100571327","NCT06718816","Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD","A Long-term Follow-up Study to Evaluate the Safety and Effectivity of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Mecular Degeneration (wAMD)","Inclusion Criteria:\n\n* The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.\n* The subject or their legal representative agrees to participate in this study and signs a written ICF.\n* The subjects are willing and able to follow planned visits and procedures.\n\nExclusion Criteria:\n\n* None",{"count":100,"type":20},21,"OBSERVATIONAL","This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.",[26],"RECRUITING","2024-12-02",{"date":107,"type":31},"2024-12-05",{"date":109,"type":20},"2024-12-09",{"date":111,"type":20},"2029-06-30",{"name":91,"class":67}]